IMMIX BIOPHARMA, INC. Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest
IMMIX BIOPHARMA, INC. (IMMX) reported Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest of -$15.38 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Income Statement
us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest · last filed 2024-03-29
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), tax, portion attributable to noncontrolling interest for the quarter ending 2023-12-31 was -$5.00M.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), tax, portion attributable to noncontrolling interest for the quarter ending 2023-09-30 was -$4.31M.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), tax, portion attributable to noncontrolling interest for the quarter ending 2022-12-31 was -$3.77M.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), tax, portion attributable to noncontrolling interest for the quarter ending 2022-09-30 was -$1.58M.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), tax, portion attributable to noncontrolling interest for fiscal 2023 was -$15.38M.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), tax, portion attributable to noncontrolling interest for fiscal 2022 was -$8.27M.
| Period end | Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest 3 month | Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest 6 month | Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest 9 month | Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$9.32M derived: sum of 2 quarters · filed 2024-03-29 | -$15.38M 10-K · filed 2024-03-29 | |
| 2023-09-30 | -$4.31M 10-Q · filed 2023-11-13 | -$10.38M 10-Q · filed 2023-11-13 | ||
| 2022-12-31 | -$3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$5.35M derived: sum of 2 quarters · filed 2024-03-29 | -$8.27M 10-K · filed 2024-03-29 | |
| 2022-09-30 | -$1.58M 10-Q · filed 2023-11-13 | -$4.49M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |